Article Text
Correspondence response
Response to: ‘Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter’ by Sbeih et al
Statistics from Altmetric.com
We thank Sbeih et al for their interest in our work. In their correspondence, they show longer time taken to achieve the Lupus Low Disease Activity State (LLDAS) and ‘remission’ than the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) endpoint in a case series of 50 patients with SLE and active disease treated with intravenous belimumab 10 mg/kg.1 Sbeih et al state that the analyses we undertook in the study by Oon et al,2 which was a post hoc evaluation of BLISS-52 and BLISS-76 trials for the LLDAS endpoint, ‘lack data on the time needed to achieve LLDAS…’. However, this is not correct. In supplementary figure 1A) of the publication by Oon et al …